Clinical Trial Update: A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC [Phase 2]

View source ↗

Summary

This is a Phase 2, single-center study evaluating donafenib in combination with a PD-1 inhibitor and transarterial chemoembolization as first-line therapy for a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Donafenib (donafenib)
• PD-1 inhibitor

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Donafenib | Phase 2 | Status: COMPLETED